Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Dalian Medical UniversityActive in the last 2 years

Qihang Yuan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7516-7620; OpenAlex author ID A5065336739. Sources: OpenAlex.

Their work

Papers
15 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: 4 papers

Papers 15

  1. Integrative multi-omics analysis reveals the role of toll-like receptor signaling in pancreatic cancer. Co-author DOI 10.1038/s41598-024-84062-3↗
  2. Determining a robust prognostic biomarker for 804 patients with pancreatic cancer using a machine learning computational framework. Co-author DOI 10.1097/js9.0000000000002016↗
  3. One-carbon metabolic reprogramming and its relationship with tumor-infiltrating lymphocytes and Immune checkpoint in Pancreatic cancer Co-author DOI 10.21203/rs.3.rs-6404670/v1↗
  4. The Molecular Characteristics and Therapeutic Implications of O-glycan Synthesis in Pancreatic Cancer by Integrating Transcriptome and Single-cell Data. Co-author DOI 10.2174/0109298673293445240409060446↗
  5. Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics. First author DOI 10.1038/s41598-024-68385-9↗
  6. Letter to the editor ‘Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection’ Co-author DOI 10.1097/js9.0000000000001555↗
  7. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo. First author DOI 10.1007/s10142-023-01158-1↗
  8. Integrated single-cell and bulk RNA sequencing revealed the molecular characteristics and prognostic roles of neutrophils in pancreatic cancer. Last author DOI 10.18632/aging.205044↗
  9. Determination and characterization of molecular heterogeneity and precision medicine strategies of patients with pancreatic cancer and pancreatic neuroendocrin… First author DOI 10.3389/fendo.2023.1127441↗
  10. Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategies in patients with pancreatic cancer. First author DOI 10.3389/fonc.2023.1227606↗
  11. Contributions and prognostic performances of m7G RNA regulators in pancreatic adenocarcinoma. Co-author DOI 10.1097/cm9.0000000000002179↗
  12. Characterization of neuroendocrine regulation- and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and imm… First author DOI 10.3389/fendo.2022.1078424↗
  13. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma. Co-author DOI 10.1080/21655979.2021.1933868↗
  14. Circulating leptin and adiponectin levels in patients with pancreatic cancer. Co-author DOI 10.1097/cm9.0000000000001509↗
  15. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Net… Co-author DOI 10.3389/fgene.2021.692953↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dong Shang · 6 shared papers, 2021–2025 · strength 1.10
  2. Xu Chen · 6 shared papers, 2021–2024 · strength 1.08
  3. Dong Shang · 3 shared papers, 2022–2024 · strength 0.80
  4. Biao Zhang · 4 shared papers, 2021–2025 · strength 0.75
  5. Dong Shang · 2 shared papers, 2024–2025 · strength 0.58
  6. Shuang Li · 3 shared papers, 2021–2022 · strength 0.46
  7. Shilin Xia · 2 shared papers, 2023–2025 · strength 0.44
  8. Dawei Deng · 2 shared papers, 2021–2025 · strength 0.40
  9. Xueying Shi · 2 shared papers, 2023 · strength 0.37
  10. Zhizhou Wang · 2 shared papers, 2022–2023 · strength 0.34
  11. Yong Zhang · 1 shared paper, 2025 · strength 0.33
  12. Jie Peng · 1 shared paper, 2025 · strength 0.33
  13. Binqian Huang · 1 shared paper, 2025 · strength 0.26
  14. Jifeng Liu · 1 shared paper, 2025 · strength 0.26
  15. Peng Yi · 1 shared paper, 2025 · strength 0.25
  16. Bing Qi · 1 shared paper, 2024 · strength 0.22
  17. Jifeng Liu · 1 shared paper, 2024 · strength 0.22
  18. Shuang Li · 1 shared paper, 2024 · strength 0.22
  19. Xu Chen · 1 shared paper, 2022 · strength 0.20
  20. Hui Guo · 1 shared paper, 2023 · strength 0.19
  21. Yougang Cui · 1 shared paper, 2023 · strength 0.18
  22. Fangyue Guo · 1 shared paper, 2023 · strength 0.18
  23. Ning Li · 1 shared paper, 2023 · strength 0.18
  24. Changmiao Wang · 1 shared paper, 2023 · strength 0.18
  25. Zhizhou Wang · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.